Micafungin Sodium CAS NO 208538-73-2 Inquire about Micafungin Sodium

Tecoland supplies Micafungin Sodium bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Micafungin Sodium is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.

What is Micafungin Sodium?

Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1, 3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in theEuropean Union on April 25, 2008.

What is the indication of Micafungin Sodium?

Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, Candida peritonitis, abscessesand esophageal candidiasis. Since January 23, 2008, micafungin has been approved for the prophylaxis of Candidainfections in patients undergoing hematopoietic stem cell transplantation (HSCT).

Micafungin works by way of concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, which is an essential polysaccharide comprising one-third of the majority of Candida spp. cell walls. This decreased glucan production leads to osmotic instability and thus cellular lysis.

Disclaimer:

Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.